10x Genomics announces preliminary Q4 and full year 2023 results

10x Genomics, Inc. announced preliminary, unaudited select results for the fourth quarter and full year ended December 31, 2023.

Preliminary, unaudited select fourth quarter 2023 financial results

• Revenue of approximately $184.0 million for the three months ended December 31, 2023, representing 18% growth over the corresponding prior year period.
• Instruments revenue of approximately $38.4 million, representing 72% growth over the corresponding prior year period. Instruments revenue consists of approximately $11.1 million Chromium instruments revenue and $27.2 million Spatial instruments revenue.
• Consumables revenue of approximately $140.3 million, representing 7% growth over the corresponding prior year period. Consumables revenue consists of approximately $118.1 million Chromium consumables revenue and $22.2 million Spatial consumables revenue.
• Services revenue of approximately $5.3 million, representing 129% growth over the corresponding prior year period.

Preliminary, unaudited select full year 2023 financial results

• Revenue of approximately $618.7 million for the year ended December 31, 2023, representing 20% growth over the prior year.
• Instruments revenue of approximately $123.5 million, representing 71% growth over the prior year. Instruments revenue consists of approximately $47.9 million Chromium instruments revenue and $75.6 million Spatial instruments revenue.
• Consumables revenue of approximately $479.6 million, representing 10% growth over the prior year. Consumables revenue consists of approximately $420.3 million Chromium consumables revenue and $59.2 million Spatial consumables revenue.
• Services revenue of approximately $15.7 million, representing 86% growth over the prior year.
• Increased cumulative instruments sold to more than 5,900 as of the end of 2023, which includes over 5,150 Chromium instruments, over 500 Visium instruments and over 250 Xenium instruments.

Preliminary revenue subject to adjustment
10x Genomics, Inc. has not completed preparation of its financial statements for the fourth quarter or full year of 2023. The revenue estimates presented in this news release for the quarter and year ended December 31, 2023 are preliminary and unaudited and are thus inherently uncertain and subject to change as we complete preparation of our financial statements for the fourth quarter and year ended December 31, 2023. 10x Genomics, Inc. is in the process of completing its customary year-end close and review procedures as of and for the quarter and year ended December 31, 2023, and there can be no assurance that final results for these periods will not differ from these estimates. During the course of the preparation of 10x Genomics, Inc.’s consolidated financial statements and related notes as of and for the year ended December 31, 2023, we or our independent registered public accountants may identify items that could cause final reported results to be materially different from the preliminary financial estimates presented herein.

10x Genomics, Inc. plans to report final financial results for the quarter and year ended December 31, 2023 in its February 2024 earnings call.
MB Bureau